Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial

Schizophrenia Research

Volumn 134, Issue 2-3, 2012, Pages 207-210

  Boggs, Douglas L ^a   Kelly, Deanna L ^b   McMahon, Robert P ^b   Gold, James M ^b   Gorelick, David A ^c   Linthicum, Jared ^b   Conley, Robert R ^d   Liu, Fang ^b   Waltz, James ^b   Huestis, Marilyn A ^c   Buchanan, Robert W ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

CB1 receptor antagonist; Cognition; Probabilistic learning; Rimonabant; Schizophrenia

Indexed keywords

PLACEBO; RIMONABANT;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LEARNING; NEUROCOGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; TASK PERFORMANCE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; COGNITION DISORDERS; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; PYRAZOLES; RECEPTORS, CANNABINOID; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856265805     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.11.009     Document Type: Article

References (26)

1. American Psychiatric Association Diagnostic Criteria from DSM-IV-TR 2000, The Association, Washington, D.C.
2. Andre V.M., Cepeda C., Cummings D.M., et al. Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids. Eur. J. Neurosci. 2010, 31(1):14-28.
3. Bechara A., Damasio A.R., Damasio H., Anderson S.W. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 1994, 50(1-3):7-15.
4. Cohen J.D., Perlstein W.M., Braver T.S., et al. Temporal dynamics of brain activation during a working memory task. Nature 1997, 386:604-608.
5. Eggan S.M., Hashimoto T., Lewis D.A. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry 2008, 65(7):772-784.
6. Frank M.J., O'Reilly R.C. A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol. Behav. Neurosci. 2006, 120:497-517.
7. Frank M.J., Seeberger L.C., O'Reilly R.C. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 2004, 306(5703):1940-1943.
8. Garcia-Arencibia M., Ferraro L., Tanganelli S., et al. Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. Neurosci. Lett. 2008, 438(1):10-13.
9. Gold J.M., Queern C., Iannone V.N., Buchanan R.W. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, I: sensitivity, reliability, and validity. Am. J. Psychiatry 1999, 156:1944-1950.
10. Hobart M.P., Goldberg R., Bartko J.J., Gold J.M. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, II: convergent/discriminant validity and diagnostic group comparisons. Am. J. Psychiatry 1999, 156:1951-1957.
11. Horder J., Cowen P.J., Di Simplicio M., et al. Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology (Berl) 2009, 205(1):85-91.
12. Horder J., Harmer C.J., Cowen P.J., McCabe C. Reduced neural response to reward following 7 days treatment with the cannabinoid CB(1) antagonist rimonabant in healthy volunteers. Int. J. Neuropsychopharmacol. 2010, 13(8):1103-1113.
13. Kelly D., Gorelick D., Conley R., et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight patients with schizophrenia: a randomized, double-blind pilot study. J. Clin. Psychopharmacol. 2011, 31(1):86-91.
14. Lai, K., Kelley, K., in press. Accuracy in parameter estimation for ANCOVA and ANOVA contrasts: Sample size planning via narrow confidence intervals. Br J Mathematical and Statistical Psychology. doi:10.1111/j.2044-8317.2011.02029.x (Electronic publication ahead of print). http://www.ncbi.nlm.nih.gov/pubmed/22004142.
15. Lewis D.A., Sweet R.A. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J. Clin. Invest. 2009, 119(4):706-716.
16. Lichtman A.H. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur. J. Pharmacol. 2000, 404:175-179.
17. Macmillan N.A., Creelman C.D. Response bias: characteristics of detection theory, threshold theory, and "nonparametric" indexes. Psychol. Bull. 1990, 107(3):401-413.
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
19. Shiflett M.W., Rankin A.Z., Tomaszycki M.L., DeVoogd T.J. Cannabinoid inhibition improves memory in food-storing birds, but with a cost. Proc. Biol. Sci. 2004, 271:2043-2048.
20. Sim-Selley L.J., Brunk L.K., Selley D.E. Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur. J. Pharmacol. 2001, 414(2-3):135-143.
21. Tadaiesky M.T., Dombrowski P.A., Da Cunha C., et al. Effects of SR141716A on cognitive and depression-related behavior in an animal model of premotor Parkinson's disease. Park. Dis. 2010, 1-6.
22. Terranova J.P., Storme J.J., Lafon N., et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) 1996, 126:165-172.
23. Varvel S.A., Lichtman A.H. Evaluation of CB1 receptor knockout mice in the Morris water maze. J. Pharmacol. Exp. Ther. 2002, 301:915-924.
24. Varvel S.A., Anum E.A., Lichtman A.H. Disruption of CB(1) receptor signaling impairs extinction of spatial memory in mice. Psychopharmacology (Berl) 2005, 179:863-872.
25. Waltz J.A., Frank M.J., Wiecki T.V., Gold J.M. Altered probabilistic learning and response biases in schizophrenia: behavioral evidence and neurocomputational modeling. Neuropsychology 2011, 25:86-97.
26. Wilk C.M., Gold J.M., Bartko J.J., et al. Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am. J. Psychiatry 2002, 159(5):838-844.